Browse the evidence

Higher genetically predicted BMI causally increases the risk of renal, acute diabetic crisis, and infective deaths.

Higher BMI is strongly linked to death from kidney disease, severe diabetic episodes, and infections. Preventing these outcomes requires addressing underlying metabolic health.

Energy expenditure can be increased through specific physiological mechanisms independent of physical activity, including UCP1-dependent thermogenesis in brown/beige fat, futile cycling of substrates (creatine, glucose, lipids), and ion pumping (Na+/K+-ATPase, SERCA).

Your body burns calories through several active processes beyond just moving around. These include generating heat in fat tissue (thermogenesis), running 'futile' metabolic cycles that burn energy as heat, and maintaining electrical gradients in cells. While you can't easily control these directly, understanding them helps explain why some medications work better than others. Future treatments may target these specific pathways to help you burn more calories passively.

Semaglutide provides robust cardiovascular risk reduction (MACE) in patients with Type 2 Diabetes and established cardiovascular disease, independent of glycemic control improvements.

If you have obesity and established heart disease, semaglutide (2.4mg weekly) significantly reduces your risk of major adverse cardiovascular events (MACE), even if you do not have diabetes. This benefit is driven by weight loss and cardiometabolic improvement, not just blood sugar control.

Heart disease and stroke remain the leading causes of death globally, with significant disparities in prevalence and mortality across different racial and ethnic groups, necessitating targeted public health interventions to address structural racism and health equity.

Focus on managing key risk factors like blood pressure, cholesterol, and blood sugar, while being aware of and addressing potential systemic barriers to healthcare access.

Obesity drives insulin resistance and type 2 diabetes through the accumulation of free fatty acids and pro-inflammatory cytokines in non-adipose tissues, which activate kinases (PKC, JNK, IKKβ) that inhibit insulin receptor signaling.

If you have obesity, your risk for type 2 diabetes is significantly higher due to biological changes in your fat tissue and blood. This isn't just about 'eating less'; it's about how your body processes energy. Addressing obesity through sustainable lifestyle changes can mitigate these specific biological risks.

Body weight regulation is not governed by a single fixed set-point, but rather by a dynamic equilibrium where energy expenditure passively adjusts to match intake, creating a 'zone of indifference' bounded by upper and lower intervention points.

Do not assume your body has a rigid 'set point' that fights against you. Your weight settles at a level where your energy expenditure matches your intake. If your environment changes (e.g., more food, less activity), your weight will drift until your expenditure rises to match the new intake. Understanding this passive feedback helps explain why small, sustained environmental changes lead to gradual weight gain over years.

Intermittent energy restriction (IER) diets (time-restricted eating, alternate-day fasting, and 5:2 diet) do not produce superior improvements in body weight, fat mass, or cardiometabolic risk markers compared to continuous energy restriction (CER) when total energy intake is matched.

If your goal is weight loss or better metabolic health, you do not need to adopt a complex intermittent fasting schedule. A standard daily calorie restriction diet is equally effective. Focus on maintaining a consistent caloric deficit rather than restricting your eating window, unless you personally prefer the structure of fasting.

High systolic blood pressure (SBP) is a leading metabolic risk factor globally, contributing to 7.8% of total disability-adjusted life-years (DALYs) in 2021, with an increasing annual exposure rate of 1.8%.

High blood pressure is a major driver of global disease burden. Regular monitoring and management are crucial for long-term health.

Chronic low-grade inflammation (inflammaging) is a fundamental endogenous driver of aging, creating a vicious cycle with cellular senescence that leads to organ dysfunction and age-related diseases.

Aging is closely linked to chronic, low-grade inflammation. While this paper is a mechanistic review, the implication is that strategies reducing systemic inflammation may support healthy aging. Focus on lifestyle factors known to modulate inflammation, such as regular physical activity, adequate sleep, and a nutrient-dense diet, as these are foundational to managing 'inflammaging'.

Immunosenescence, characterized by a decline in immune cell function and an increase in pro-inflammatory cytokine secretion, impairs the clearance of senescent cells and pathogens, exacerbating aging.

Immune function declines with age, leading to increased susceptibility to infection and chronic inflammation. Maintaining immune health through vaccination, stress management, and nutrient adequacy is crucial for older adults.

Persistent hyperglycemia accelerates endogenous AGE formation through the Maillard reaction and dicarbonyl stress, leading to RAGE activation, oxidative stress, and insulin resistance.

Maintaining blood glucose levels within target ranges is critical to preventing the formation of endogenous AGEs and subsequent tissue damage.

Accelerated biological aging of specific organs, measured via plasma proteomic signatures, significantly increases the risk of organ-specific diseases and all-cause mortality, independent of chronological age.

Your chronological age is not your biological destiny. This research shows that your organs age at different rates, and accelerated aging in specific organs (like the heart or brain) is a strong predictor of future disease and mortality, independent of how many birthdays you've had. While this specific test is not yet standard care, the key takeaway is that organ-specific health monitoring is crucial. Focus on maintaining the health of your most vulnerable organs through targeted lifestyle interventions, as organ-specific aging is a modifiable risk factor for major diseases like heart failure and Alzheimer's.

Gestational diabetes mellitus (GDM) is the most prominent independent risk factor for the progression to type 2 diabetes in women, increasing the relative risk by approximately 8.3-fold.

If you had gestational diabetes, your risk of developing type 2 diabetes is over 8 times higher than women who did not. This risk persists for years. You need lifelong, regular glucose monitoring and lifestyle interventions, as standard postpartum care often neglects this long-term metabolic risk.

Chronic low-grade inflammation (inflammaging) acts as a bidirectional driver that exacerbates all other hallmarks of aging, creating a vicious cycle that accelerates biological aging and age-related diseases.

Chronic, low-grade inflammation is a central accelerator of aging. While not an intervention itself, understanding 'inflammaging' highlights the importance of lifestyle factors (diet, exercise) that modulate immune response and reduce this persistent inflammatory state, thereby potentially slowing the progression of age-related diseases.

Tirzepatide is associated with a higher incidence of gastrointestinal adverse events (nausea, vomiting, diarrhea) compared to placebo and basal insulin, which can lead to treatment discontinuation.

Tirzepatide often causes stomach problems like nausea, vomiting, and diarrhea, especially at higher doses (10mg and 15mg). These side effects are more common than with placebo or basal insulin and can cause some people to stop taking the medication. Starting at a lower dose and increasing slowly may help.

Chronic treatment with GDF15 promotes greater weight loss and reduces NAFLD compared to caloric restriction alone by maintaining energy expenditure and preventing adaptive thermogenesis in skeletal muscle.

This research suggests that GDF15 therapy could help overcome the metabolic slowdown (adaptive thermogenesis) that typically halts weight loss during dieting. By maintaining energy expenditure, particularly through fatty acid oxidation in muscle, GDF15 allows for greater fat loss than dieting alone. This is relevant for individuals who hit weight loss plateaus despite strict caloric restriction.

GDF15 maintains energy expenditure and promotes weight loss through a GFRAL-dependent signaling axis that activates beta-adrenergic receptors in skeletal muscle, increasing fatty acid oxidation and calcium futile cycling.

The weight loss benefits of GDF15 rely on a specific biological pathway involving the GFRAL receptor and beta-adrenergic signaling in muscles. If this pathway is blocked or missing, the energy expenditure benefits are lost.

Epigenetic aging, as measured by the Skin&blood clock, is distinct from cellular senescence, telomere attrition, and genomic instability, but is associated with nutrient sensing, mitochondrial activity, and stem cell composition.

Epigenetic age is not a simple proxy for cellular damage or telomere length. Interventions that extend lifespan (like caloric restriction or rapamycin) slow epigenetic aging, while those that extend lifespan via other mechanisms (like NAD precursors or metformin in this specific context) may not. To influence epigenetic age, focus on nutrient sensing (mTOR pathway) and mitochondrial health, as these are mechanistically linked to the clock's ticking, distinct from DNA repair or telomere maintenance.

Consumer-grade wearable devices are not exempt from rigorous performance evaluation simply because they are marketed as 'research' or 'clinical' grade, as proprietary algorithms and hardware inconsistencies can still lead to significant errors.

Do not assume a device is accurate because it is 'clinical grade' or 'FDA cleared'. You must validate the specific device's sleep staging accuracy against PSG for your specific study population before using it for research conclusions.

Peptide 20, a GIPR/GLP-1R/GCGR tri-agonist, achieves balanced potency across all three receptors through specific structural modifications, including lipidation of K10P, which stabilizes binding and enhances receptor-mediated cAMP accumulation.

Peptide 20 is a complex drug that activates three metabolic receptors (GIP, GLP-1, Glucagon) simultaneously. Its effectiveness relies on specific chemical modifications (lipidation) that stabilize the drug's binding to these receptors, leading to significant improvements in blood sugar, weight, and glucose tolerance in animal models.

Bariatric/metabolic surgery (BMS) is the most effective strategy for significant and sustained body weight reduction (14-25%) and reduces the risk of hypertension, diabetes, and mortality, but remains underused.

For extreme obesity (BMI ≥ 40 or ≥ 35 with comorbidities), bariatric surgery is the most effective treatment, producing 14-25% weight loss and significantly reducing the risk of heart disease, diabetes, and death. Despite its effectiveness, it is underused. If lifestyle and medication fail, discuss surgery with your doctor as a viable, life-saving option.

Leptin signaling via hypothalamic LepRbGlp1r neurons is the primary driver of food intake suppression, as ablating this receptor causes hyperphagic obesity without impairing energy expenditure.

This research identifies a specific brain pathway (LepRbGlp1r neurons) that leptin uses to tell you to stop eating. When this pathway is broken or ignored, you eat more regardless of how much energy you burn. This explains why some obesity treatments focus on mimicking these signals (like GLP-1 drugs) to restore the 'stop eating' signal rather than just forcing exercise.

Bariatric surgery is currently the most effective treatment for obesity in terms of mortality reduction and comorbidity resolution, but it is restricted to higher BMI classes and not suitable for all patients.

Bariatric surgery is the most effective treatment for obesity, significantly reducing mortality and type 2 diabetes risk, but it is generally reserved for patients with Class II or III obesity (BMI ≥ 35 or ≥ 40) and is not suitable for everyone due to surgical risks and access issues.

SGLT2 inhibitors provide significant cardiovascular and renal protection in patients with type 2 diabetes, heart failure, and chronic kidney disease, independent of glycemic control.

If you have Type 2 Diabetes along with heart failure or kidney disease, SGLT2 inhibitors (like Jardiance, Farxiga, or Trulicity's cousin) are now a standard, first-line treatment. They protect your heart and kidneys regardless of your blood sugar numbers. Discuss starting one with your doctor immediately, as guidelines strongly recommend it for this specific patient profile.